Fig. 2

Differences in seroconversion between vaccination groups. The differences in seroconversion between vaccination groups are presented with Farrington-Manning 90% Confidence Interval around the estimated difference. The red line is the non-inferiority margin, set at -5%. “Coadministration minus First Dose” is the difference in the seroconversion following co-administration (MMR₁YF₁) minus the seroconversion following individual administration of the vaccine as the first vaccine in a 2-dose series (MMR₁YF₂ or YF₁MMR₂ ). “Coadministration minus Second Dose” is the difference in seroconversion following co-administration minus the seroconversion following individual administration as the second vaccine in a 2-dose series separated by four weeks. “Second Dose minus First Dose” is the difference in the seroconversion following individual administration as the second dose in a 2-dose series separated by four weeks minus the seroconversion following administration as the first vaccine in the series. In this intention-to-treat analysis, seroconversion following co-administration was non-inferior to seroconversion following individual administration as the first or second dose for all antigens. Non-inferiority in seroconversion was not shown for measles, mumps, and rubella when MMR was administered as the second vaccine as compared to when it was administered as the first vaccine in the series separated by four weeks